Patricia Lugar, MD, MS, Duke Health

home / authors / patricia-lugar-md-ms-duke-health

Articles

Daniel J. DeAngelo, MD, PhD;Prithviraj Bose, MD;Patricia Lugar, MD, MS, Duke Health;Sa Wang, MD, MD Anderson Cancer Center

September 27th 2021

The panel of experts in SM highlight the unmet needs in the clinical care of systemic mastocytosis.

Case 3: Indolent Systemic Mastocytosis

Daniel J. DeAngelo, MD, PhD, Dana-Farber Cancer Institute;Patricia Lugar, MD, MS, Duke Health;Prithviraj Bose, MD, MD Anderson Cancer Center

September 7th 2021

Dan DeAngelo, MD, PhD, presents the case of a patient with indolent systemic mastocytosis and urticaria pigmentosa.

Avapritinib: Approval and Clinical Practice Implications

Daniel J. DeAngelo, MD, PhD, Dana-Farber Cancer Institute;Prithviraj Bose, MD, MD Anderson Cancer Center;Patricia Lugar, MD, MS, Duke Health

September 7th 2021

A panel of experts share their reactions to the approval of avapritinib and discuss the clinical implications.

Case 2: SM Treatment Algorithm and Supportive Care Recommendations

Daniel J. DeAngelo, MD, PhD, Dana-Farber Cancer Institute;Patricia Lugar, MD, MS, Duke Health

August 30th 2021

Patricia Lugar, MD, MS, shares an allergist’s perspective regarding treatment algorithms and supportive care recommendations for patients with systemic mastocytosis.

Case 1: Treatment Algorithm and Supportive Care Recommendations

Daniel J. DeAngelo, MD, PhD, Dana-Farber Cancer Institute;Sa Wang, MD, MD Anderson Cancer Center;Prithviraj Bose, MD, MD Anderson Cancer Center;Patricia Lugar, MD, MS, Duke Health

August 16th 2021

Patricia Lugar, MD, MS, shares treatment algorithm and supportive care recommendations for a 75-year-old man with systemic mastocytosis.

Case 1: Treatment and Management Considerations

Daniel J. DeAngelo, MD, PhD, Dana-Farber Cancer Institute;Sa Wang, MD, MD Anderson Cancer Center;Prithviraj Bose, MD, MD Anderson Cancer Center;Patricia Lugar, MD, MS, Duke Health

August 16th 2021

The panel of experts in SM discuss the diagnosis and management of a 75-year-old man with systemic mastocytosis.

Case 1: 75-Year-Old Man With SM

Daniel J. DeAngelo, MD, PhD, Dana-Farber Cancer Institute;Sa Wang, MD, MD Anderson Cancer Center;Prithviraj Bose, MD, MD Anderson Cancer Center;Patricia Lugar, MD, MS, Duke Health

August 9th 2021

Dan DeAngelo, MD, PhD, presents the case of a 75-year-old man with systemic mastocytosis and reviews WHO diagnostic criteria.

Considerations in SM: Hereditary Alpha Tryptasemia

Daniel J. DeAngelo, MD, PhD, Dana-Farber Cancer Institute;Sa Wang, MD, MD Anderson Cancer Center;Prithviraj Bose, MD, MD Anderson Cancer Center;Patricia Lugar, MD, MS, Duke Health

August 9th 2021

Prithviraj Bose, MD, and Patricia Lugar, MD, MS, discuss the considerations and testing options for hereditary alpha tryptasemia in patients with systemic mastocytosis.